Literature DB >> 10841080

VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence.

B Stoelcker1, B Echtenacher, H A Weich, H Sztajer, D J Hicklin, D N Männel.   

Abstract

Vascular endothelial growth factor (VEGF) plays an important role in the production of ascitic fluid associated with malignant tumor growth. In an experimental model for malignant ascites formation, mice were inoculated intraperitoneally with syngeneic mouse sarcoma tumor cells. Ascites development was not prevented by administering tumor necrosis factor (TNF) simultaneously with the tumor cell inoculation. When the malignant ascites was first drained and renewal of ascites was monitored, however, a TNF dose-dependent inhibition of ascitic fluid accumulation was observed. Northern blot analyses indicated transient downregulation by TNF on the expression of VEGF mRNA in tumor cells. Monoclonal antibody, (mAb) DC101 generated against the mouse VEGF receptor Flk-1 prevented the recurrence of malignant ascites in mice similar to TNF inhibition. In addition, exogenous soluble human Flt-1 used as an inhibitor of endogenous VEGF binding also inhibited ascites recurrence. These data demonstrate that the observed inhibitory effect of TNF on reestablishment of malignant ascites can be achieved equally by inhibition of the interaction of VEGF with its receptor Flk-1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10841080     DOI: 10.1089/10799900050023933

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  6 in total

1.  Regulation of angiogenesis during osseointegration by titanium surface microstructure and energy.

Authors:  Andrew L Raines; Rene Olivares-Navarrete; Marco Wieland; David L Cochran; Zvi Schwartz; Barbara D Boyan
Journal:  Biomaterials       Date:  2010-03-30       Impact factor: 12.479

Review 2.  Malignant ascites: pathophysiology and treatment.

Authors:  Emanuel Cavazzoni; Walter Bugiantella; Luigina Graziosi; Maria Silvia Franceschini; Annibale Donini
Journal:  Int J Clin Oncol       Date:  2012-03-31       Impact factor: 3.402

3.  Antiangiogenic effect of 2-benzoyl-phenoxy acetamide in EAT cell is mediated by HIF-1alpha and down regulation of VEGF of in-vivo.

Authors:  B T Prabhakar; Shaukath Ara Khanum; S Shashikanth; Bharathi P Salimath
Journal:  Invest New Drugs       Date:  2006-11       Impact factor: 3.850

4.  Emerging treatment options for management of malignant ascites in patients with ovarian cancer.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Int J Womens Health       Date:  2012-08-03

5.  Curcumin inhibits angiogenesis and improves defective hematopoiesis induced by tumor-derived VEGF in tumor model through modulating VEGF-VEGFR2 signaling pathway.

Authors:  Zhongping Fu; Xiao Chen; Shengwen Guan; Yanju Yan; Huan Lin; Zi-Chun Hua
Journal:  Oncotarget       Date:  2015-08-14

6.  Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients.

Authors:  Dawei Chen; Yan Zhang; Fang Shi; Hui Zhu; Minghuan Li; Judong Luo; Kaijun Chen; Li Kong; Jinming Yu
Journal:  Oncotarget       Date:  2016-08-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.